Trials Sponsors Conditions Drugs Pricing

Conditions

Glioblastoma

Outcome Measures

Primary Outcomes (7)

Overall Survival
1 year from last patient in
Molecular profiling on FFPE samples
Profiling for cytosine-phosphate-guanosine (CpG) methylation patterns using the Illumina 850k bead array platform
1 year from last patient in
Molecular profiling on frozen samples
Samples will be subjected to whole exome sequencing
1 year from last patient in
Molecular profiling on frozen samples
Samples will be subjected to messenger ribonucleic acid (mRNA) sequencing
1 year from last patient in
Molecular profiling on frozen samples
Samples will be subjected to miRNA sequencing
1 year from last patient in
Molecular profiling on frozen samples
Samples will be subjected to microarray-based expression profiling
1 year from last patient in
Proteome profiling
Tumor cells will be microdissected from frozen sections and prepared for high-resolution mass spectrometry
1 year from last patient in

Interventions

Blood drawlProcedure

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Glioblastoma patients with overall survival \> 5 years

You may qualify if:

Age \> 18 years at diagnosis

Sponsors & Collaborators

European Organisation for Research and Treatment of Cancer - EORTC
Research networklead

Study Sites (27)

Dana-Farber Cancer Institute & Harvard Medical School

Boston, Massachusetts, 02115-5450, United States

Universitaetsklinikum Wien - AKH uniklinieken

Vienna, 1090, Austria

Hopitaux Universitaires Bordet-Erasme

Brussels, 1070, Belgium

CHU Lyon - Hopital neurologique Pierre Wertheimer

Bron, 69677, France

CHRU de Lille

Lille, France

Hopitaux de Marseille - Hôpital de La Timone (APHM)

Marseille, 13385, France

Institut du Cancer de Montpellier

Montpellier, 34298, France

MeSH Terms

Conditions

Glioblastoma

Condition Hierarchy (Ancestors)

AstrocytomaGliomaNeoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Glandular and EpithelialNeoplasms, Nerve Tissue

Study Officials

Michael Weller
EORTC Study Coordinator
PRINCIPAL INVESTIGATOR

Enrollment

599 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: OTHER
Time Perspective: CROSS SECTIONAL
Sponsor Type: NETWORK
Responsible Party: SPONSOR

Study Record Dates

First Submitted

November 18, 2018

First Posted

December 10, 2018

Study Start

July 5, 2015

Actual (reported)

Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (7)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (27)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (7)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (27)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations